Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

pembrolizumab 8cemiplimab 5Nivolumab 4Ipilimumab 4Blood Specimen Collection 3lifileucel 2avelumab 2aldesleukin 2Niacinamide 2Cyclophosphamide 2toripalimab 1tislelizumab 1oxycodone-acetaminophen 1lenvatinib 1fludarabine 1epacadostat 1encorafenib 1durvalumab 1dostarlimab 1brodalumab 1binimetinib 1atezolizumab 1Vitamin A 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Specimen Handling 1Resistance Training 1Radiotherapy 1Niacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Skin Neoplasms × Ipilimumab × 90 days × Clear all
NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital

Phase 2 Recruiting
37 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Incyte Corporation

Phase 1/2 Terminated
50 enrolled
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
29 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡